Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 26 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Pembrolizumab and chemotherapy with or without radiotherapy as an adjuvant therapy for treating newly diagnosed high-risk endometrial cancer	Chemotherapy , Pembrolizumab (Keytruda; MK-3475)	Endometrial cancer	Female Reproductive Cancer	2022	View \| Download
Nivolumab with chemotherapy neoadjuvant followed by nivolumab adjuvant for treating early stage non-small-cell lung cancer	Chemotherapy , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Nivolumab in combination with chemotherapy for previously untreated unresectable or metastatic urothelial cancer	Chemotherapy , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Urothelial cancer	Urological Cancer	2022	View \| Download
Nivolumab in combination with chemotherapy for early-stage non-small cell lung cancer – neoadjuvant	Chemotherapy , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Nivolumab in addition to chemotherapy for advanced gastric cancer – first line	Chemotherapy , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Gastric cancer	Gastrointestinal Cancer	2018	View \| Download
Niraparib as maintenance therapy for treating recurrent or primary-advanced endometrial cancer after chemotherapy in combination with dostarlimab.	Chemotherapy , Dostarlimab (TSR-042; Jemperli) , Niraparib (Zejula; MK 4827; JNJ 64091742; GSK 3985771; niraparib tosylate monohydrate)	Endometrial cancer	Female Reproductive Cancer	2023	View \| Download
Neoadjuvant atezolizumab with chemotherapy followed by adjuvant atezolizumab for treating triple-negative breast cancer	Atezolizumab (Tecentriq; MPDL3280A) , Chemotherapy	Breast cancer	Breast Cancer	2022	View \| Download
Durvalumab with platinum-based chemotherapy for the neoadjuvant/adjuvant treatment of resectable non-small-cell lung cancer	Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Durvalumab with bevacizumab and chemotherapy for treating advanced ovarian cancers	Bevacizumab (Avastin; R 435; RG 405; RG 435) , Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Ovarian cancer	Female Reproductive Cancer	2023	View \| Download
Durvalumab in addition to chemotherapy for metastatic non-small-cell lung cancer - first line	Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2019	View \| Download